Alterity Therapeutics Presents Data at Alzheimer's Conference

TL;DR

Alterity Therapeutics presented PBT2 data at an Alzheimer's conference, filing it with the SEC.

AI Summary

Alterity Therapeutics Ltd. filed a Form 6-K on October 2, 2024, to incorporate by reference into several of its existing SEC registration statements. The filing highlights the company's participation in the International Conference on Alzheimer's and Parkinson's Diseases, where it presented data on its lead drug candidate, PBT2, for treating neurodegenerative diseases.

Why It Matters

The presentation of data at a major international conference could increase investor interest and potentially advance the development and future commercialization of Alterity's neurodegenerative disease treatments.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the underlying clinical trial data and the company's stage of development carry inherent risks associated with pharmaceutical development.

Key Players & Entities

• Alterity Therapeutics Ltd. (company) — Registrant
• PBT2 (drug_candidate) — Lead drug candidate for neurodegenerative diseases
• International Conference on Alzheimer's and Parkinson's Diseases (event) — Conference where data was presented
• Form S-8 (filing) — Registration statement into which this 6-K is incorporated
• Form F-3 (filing) — Registration statement into which this 6-K is incorporated

FAQ

Filing Documents

• ea0216455-6k_alterity.htm (6-K) — 14KB
• ea021645501ex99-1_alterity.htm (EX-99.1) — 40KB
• ex99-1_001.jpg (GRAPHIC) — 4KB
• 0001213900-24-084322.txt ( ) — 61KB

From the Filing

OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: October 2, 2024 2

View Full Filing

View this 6-K filing on SEC EDGAR